FFCD and METHYS Dx: A Partnership Driving Innovation in Digestive Oncology

The Fédération Francophone de Cancérologie Digestive (FFCD) and METHYS Dx have decided to combine their expertise to contribute to the development of new approaches aimed at improving the monitoring of patients with digestive cancers.

This partnership reflects a shared ambition: to advance clinical research and foster the emergence of innovative tools to support increasingly personalized and effective patient care.

Founded in 2021, METHYS Dx is a French DeepTech company specializing in the development of liquid biopsy solutions for the non-invasive follow-up of cancer patients. Through the analysis of circulating tumor DNA (ctDNA) and its proprietary methylation signatures, the company is developing highly sensitive tests designed to support clinicians in therapeutic decision-making and strengthen precision medicine approaches.

For more than forty years, the FFCD has been a major player in clinical research in digestive oncology. Through the design and conduct of multicenter clinical trials, it actively contributes to advancing scientific knowledge and medical practice for the benefit of patients.

At the heart of this collaboration is a shared conviction: clinical research is a key driver in bringing forward innovations that will transform the management of digestive cancers. By combining their respective expertise, the FFCD and METHYS Dx aim to develop projects that assess and demonstrate the potential of liquid biopsy technologies in patient monitoring.

The solutions developed by METHYS Dx offer promising opportunities for more precise, less invasive monitoring that is better tailored to the individual needs of patients. By leveraging the FFCD’s scientific and clinical expertise, this partnership aims to accelerate the generation of new knowledge and facilitate the translation of research advances into clinical practice.

More than a collaboration, this partnership reflects a shared commitment to bringing academic research, clinical research, and technological innovation closer together in order to address the current and future challenges of digestive oncology.

Together, the FFCD and METHYS Dx share the conviction that collaboration among stakeholders across the healthcare ecosystem is essential to developing practical solutions and achieving lasting improvements in the patient care pathway.